POTASSIUM CHLORIDE

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name: POTASSIUM CHLORIDE
Generic name: POTASSIUM CHLORIDE
Manufacturer: Advagen Pharma Limited
Product type: HUMAN PRESCRIPTION DRUG
SPL set ID: a9e9d134-55d0-47ae-925f-de07e7ffa4b8
SPL ID: 47c7720f-ffb0-0750-e063-6394a90a77c8
Version: 4
Effective date: 2026-01-07
Source export date: 2026-09-28
Source partition: 13
Source file: https://download.open.fda.gov/drug/label/drug-label-0013-of-0014.json.zip
Source object key: raw/openfda/drug-label/2026-09-28/e78bf8aa9f90ab13e640d254dfbd4fe5bfeca4995ec5f9d51bce3356e249cab7/drug-label-0013-of-0014.json.zip
Source manifest SHA-256: cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
Import run: 20260929T050834Z
Imported at: 2026-09-29 06:38:50

Harmonized routes table
Harmonized routes
ORAL

Harmonized identifier links#

Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.

Harmonized identifiers page 1 of 1 · 16 matching rows.

Type, Scope, Identifier table
Type	Scope	Identifier	Source field
application applno	ANDA	214656	derived:openfda.application_number
application number		ANDA214656	openfda.application_number
brand name		POTASSIUM CHLORIDE	openfda.brand_name
generic name		POTASSIUM CHLORIDE	openfda.generic_name
manufacturer name		Advagen Pharma Limited	openfda.manufacturer_name
ndc	package	72888-041-13	openfda.package_ndc
ndc	package	72888-042-13	openfda.package_ndc
ndc	product	72888-041	openfda.product_ndc
ndc	product	72888-042	openfda.product_ndc
ndc11	package	72888004213	derived:openfda.package_ndc
ndc11	package	72888004113	derived:openfda.package_ndc
rxcui		314182	openfda.rxcui
rxcui		312515	openfda.rxcui
spl id		47c7720f-ffb0-0750-e063-6394a90a77c8	id
spl set id		a9e9d134-55d0-47ae-925f-de07e7ffa4b8	set_id
unii		660YQ98I10	openfda.unii

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Gastrointestinal Irritation : Dilute before use, take with meals ( 5.1 ) 5.1 Gastrointestinal Irritation May cause gastrointestinal irritation if administered undiluted. Increased dilution of the solution and taking with meals may reduce gastrointestinal irritation [see Dosage and Administration (2.1) ].

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 1 matching rows.

adverse reactions

6 ADVERSE REACTIONS The most common adverse reactions to oral potassium salts are nausea, vomiting, flatulence, abdominal pain/discomfort, and diarrhea. Most common adverse reactions are nausea, vomiting, flatulence, abdominal pain/discomfort, and diarrhea. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Advagen Pharma Ltd, at 866-488-0312 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.